Market closed
Entera Bio/$ENTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Entera Bio
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Ticker
$ENTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Jerusalem, Israel
Employees
19
ISIN
IL0011429839
Website
Entera Bio Metrics
BasicAdvanced
$92M
-
-$0.26
-
-
Price and volume
Market cap
$92M
52-week high
$2.58
52-week low
$1.50
Average daily volume
40K
Financial strength
Current ratio
13.073
Quick ratio
7.824
Long term debt to equity
0.263
Total debt to equity
1.135
Interest coverage (TTM)
-205.84%
Management effectiveness
Return on assets (TTM)
-39.60%
Return on equity (TTM)
-71.46%
Valuation
Price to revenue (TTM)
357.898
Price to book
4.76
Price to tangible book (TTM)
4.76
Price to free cash flow (TTM)
-12.526
Growth
Earnings per share change (TTM)
-37.65%
3-year revenue growth (CAGR)
-22.66%
3-year earnings per share growth (CAGR)
-18.86%
Entera Bio News
AllArticlesVideos
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
GlobeNewsWire·1 week ago
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
GlobeNewsWire·2 months ago
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Entera Bio stock?
Entera Bio (ENTX) has a market cap of $92M as of May 17, 2025.
What is the P/E ratio for Entera Bio stock?
The price to earnings (P/E) ratio for Entera Bio (ENTX) stock is 0 as of May 17, 2025.
Does Entera Bio stock pay dividends?
No, Entera Bio (ENTX) stock does not pay dividends to its shareholders as of May 17, 2025.
When is the next Entera Bio dividend payment date?
Entera Bio (ENTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Entera Bio?
Entera Bio (ENTX) does not currently have a Beta indicator.